This compound was originally described by Pfizer in a publication in 2010 (J Pharmacol Exp Ther. 2010 Jun; 333(3): 797-807). It has high potency towards MK2 (Ki = 3 nM) as well as PRAK (IC50 = 5 nM), MK2 (IC50 = 53 nM) and MNK2 (IC50 = 148 nM). It did not have significant activity against most of the ~200 other kinases against which it was profiled. It had significant activity (IC50 <100 nM) against the following kinases: BRSK2, CAMKII, DRAK1, PIM1, PRAK, ASK1, and MER. It is not known to what extent it has activity outside the kinome.
9 Sept 2016 )